Abbott Laboratories

Most Recent

  • Abbott Labs
    Company & Industry Overviews

    Why Abbott Labs Stock Is a Good Buy Amid the Slump

    By Adam Goodpasture
  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

    By Mike Benson
  • uploads///Q EPS
    Earnings Report

    Weighing in with Boston Scientific’s 4Q15 Revenues

    Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    Becton, Dickinson and Company’s 4Q16 Earnings Estimates

    Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.

    By Sarah Collins
  • Consumer

    Chilton Investment Company buys stake in TransDigm in 4Q13

    Chilton started a new position in aerospace engineering company TransDigm Group Inc. (TDG) that accounts for 0.76% of the fund’s fourth quarter portfolio.

    By Samantha Nielson
  • uploads///STOCK PRICE
    Earnings Report

    How Has Medtronic’s Stock Performed Recently?

    Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    How Hologic’s Valuation Stacks Up with Peers

    The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results

    On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Emerging Markets Drive Abbott’s Nutritional Business Growth

    In 1Q17, Abbott Laboratories’ (ABT) Nutritional segment reported revenue of nearly $1.6 billion, a year-over-year (or YoY) fall of ~1%.

    By Margaret Patrick
  • uploads///piron guillaume  unsplash
    Earnings Report

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

    By Sarah Collins
  • uploads///DIABETES
    Earnings Report

    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

    By Sarah Collins
  • uploads///CASH FLOW
    Company & Industry Overviews

    How Tax Reform Affected Medtronic’s 3Q18 Performance

    Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    A Look at Hologic Stock’s Recent Performance

    Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

    By Sarah Collins
  • uploads///CARDIOVASCULAR revenues
    Company & Industry Overviews

    Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?

    In its Structural Heart business, Abbott Laboratories reported 1Q18 sales of $0.29 billion, registering YoY organic sales growth of 7.5%.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Inside Abiomed’s Profit Margin Expectations for Fiscal 2018

    For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.

    By Margaret Patrick
  • uploads///Part F
    Company & Industry Overviews

    Mead Johnson Plans to Focus on R&D to Support Innovations

    Mead Johnson follows a strategy of investments in innovation, having expanded its liquids portfolio and rolled out its key specialty formulas across Asia.

    By Diana Key
  • uploads///share price on Oct
    Earnings Report

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Earnings Report

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.

    By Sarah Collins
  • uploads///core strategies
    Company & Industry Overviews

    How Are Stryker’s Core Strategies Working Toward Its Growth?

    Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

    By Sarah Collins
  • uploads///diabetes _
    Earnings Report

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Abbott Laboratories’ Stock Performance after a Recent Bull Run

    On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    European Medicines Agency Validates Merck’s Keytruda Combo

    Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

    By Mike Benson
  • uploads///stock performance
    Earnings Report

    Abbott Laboratories’ Stock Price Performance in July

    Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Company & Industry Overviews

    Trade War Fears Triggered Medtronic’s Stock Decline on March 23

    Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.

    By Sarah Collins
  • uploads///innovation strategies
    Company & Industry Overviews

    How Johnson & Johnson’s Partnerships Enhance Customer Value

    Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

    By Sarah Collins
  • uploads///hospital _
    Earnings Report

    Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings

    On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.

    By Sarah Collins
  • uploads///ALR ABT acquisition
    Company & Industry Overviews

    A Brief Look at Abbott’s Alere Integration Progress and Recovery

    Alere’s integration synergies in 1Q18 were delivered through strong performance of the company’s Rapid Diagnostics business.

    By Sarah Collins
  • uploads///hand __
    Company & Industry Overviews

    BSX Stock Regains Momentum after Its Recent Bearish Trend

    On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    A Look at Medtronic’s Recent Stock Performance

    Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.

    By Sarah Collins
  • uploads///nutrition
    Company & Industry Overviews

    Discussing Abbott’s Market Position and Growth Prospects in China

    China contributes significantly to Abbott’s Established Pharmaceuticals division, which registered sales of ~$1.1 billion, representing year-over-year growth of ~10.0%.

    By Sarah Collins
  • uploads///COMPLEMENTARY PORTFOLIO
    Company & Industry Overviews

    Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth

    On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    Boston Scientific Stock in the Week Ended September 14

    Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.

    By Sarah Collins
  • uploads///ALR ABT acquisition
    Company & Industry Overviews

    A Brief Recap of the Abbott–Alere Deal Developments

    Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Abbott’s Freestyle Libre Gets Reimbursement Approval in France

    Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.

    By Sarah Collins
  • uploads///Grph
    Company & Industry Overviews

    Can Edwards Lifesciences See Robust Net Profit Margin in 2017?

    In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

    By Margaret Patrick
  • uploads///covid  _
    Healthcare

    Gilead Sciences’ COVID-19 Drug Shows Promise

    Today at 7:55 AM ET, Gilead Sciences stock rose by 3.9% to $75.99 in the pre-market session. The company’s remdesivir drug might treat COVID-19.

    By Ambrish Shah
  • Abbott BinaxNOW COVID-19 Test Gets FDA Approval
    Healthcare

    Abbott BinaxNOW COVID-19 Test Gets FDA Approval

    By Mark Pygas
  • uploads///ABT
    Consumer

    Chilton opens a new position in Abbott Laboratories in 4Q13

    Abbott Laboratories (ABT) is a brand new position that accounts for 1.19% of Chilton’s fourth quarter 2013 portfolio.

    By Samantha Nielson
  • uploads///valuation
    Earnings Report

    Abbott Laboratories’s Valuation before Its 2Q16 Results

    After the release of its 1Q16 earnings results on April 20, 2016, Abbott Laboratories (ABT) was trading at a forward PE multiple in the range of 16.4x–19.3x.

    By Sarah Collins
  • uploads///ABMD
    Company & Industry Overviews

    Examining Abiomed’s Gross Margin Trend

    In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.

    By Kenneth Smith
  • uploads///STOCK PRICE
    Earnings Report

    Understanding JNJ’s Latest Stock Price Rise

    On July 20, 2017, JNJ stock was trading at its 52-week high of $137.1, which was ~25.4% above its 52-week low of $109.3 on December 7, 2016.

    By Sarah Collins
  • uploads///highlights
    Company & Industry Overviews

    Behind JNJ’s Recent Stock Price Performance: Is More Growth Coming?

    Johnson & Johnson (JNJ) has seen a few disappointing quarterly performances, but on October 17, when JNJ announced its 3Q17 results, the stock gained 3.4%.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    What Are Analysts Estimating for Allergan Today?

    AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).

    By Mike Benson
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///gilead sciences stock falls
    Healthcare

    Gilead Stock Falls, Coronavirus Drug Fails in Trial

    Today at 6:07 AM ET, Gilead Sciences stock fell 1.4% to $76.70 in the pre-market session. According to reports, remdesivir failed its first clinical trial.

    By Ambrish Shah
  • uploads///medic _
    Healthcare

    Abbott Laboratories Posted Its Q1 Earnings, Stock Rose 4%

    At 10:07 AM ET today, Abbott Laboratories (NYSE:ABT) stock rose by about 3.9%. The company reported its first-quarter financial results.

    By Ambrish Shah
  • uploads///laboratory _
    Healthcare

    Abbott’s Q1 Earnings Report Might Boost Its Stock

    Abbott Laboratories (NYSE:ABT) stock rose by about 1.0% in extended trading on Thursday. The stock rose 1.3% and closed at $86.04.

    By Ambrish Shah
  • uploads///Zoetis Business Model
    Financials

    Zoetis: An attractive business model

    Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”

    By Samantha Nielson
  • uploads///USB
    Consumer

    Chilton Investment Company buys a new stake in US Bancorp

    Chilton initiated a new position in the multi-state financial holding company U.S. Bancorp (USB) that accounts for 0.92% of the fund’s fourth quarter portfolio.

    By Samantha Nielson
  • uploads///Puerto Ricos GDB Economic Activity Index
    Healthcare

    Must-know market update: Is Puerto Rico losing its salsero vibe?

    The charm of the island has been overshadowed with feelings of pessimism regarding the fiscally distressed state of the economy.

    By Surbhi Jain
  • uploads///equipment _
    Earnings Report

    How Abbott Stock Reacted to the Company’s Q3 Results

    Healthcare giant Abbott Laboratories announced its third-quarter earnings results before markets opened today. Its stock was trading at $83.66 midday.

    By Shankar Iyer
  • uploads///ABT STJ product portfolio
    Company & Industry Overviews

    These Developments Impacted Abbott Laboratories the Most in Fiscal 2017

    Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    FreeStyle Libre Is Multi-Billion Dollar Opportunity for Abbott

    In the first quarter, Abbott Laboratories’ (ABT) Diabetes Care franchise reported worldwide sales of $566 million, a YoY rise of 34.4% on a reported basis.

    By Margaret Patrick
  • uploads///Pfizer stock
    Company & Industry Overviews

    Why Pfizer Stock Continues to Tank after Mylan Deal

    Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.

    By Maitali Ramkumar
  • uploads///core strategies
    Company & Industry Overviews

    How Stryker’s Margins Are Driven by Its CTG Program

    Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.

    By Sarah Collins
  • uploads///woman _
    Company & Industry Overviews

    How Do Rate Cuts Impact Healthcare Stocks?

    Barclays expects the Fed to cut the rate by 50 basis points in July—three months earlier than previously expected. Barclays expects an additional rate cut by 25 basis points in September.

    By Margaret Patrick
  • uploads///pills _
    Earnings Report

    What Wall Street Recommends for Amarin after Q4 2018 Results

    On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Boston Scientific or Abbott: Who Will Report More Revenue Growth?

    In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Abbott Laboratories’ Key Growth Drivers in 2019?

    On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Do Analysts Recommend for Abbott Laboratories in January?

    The 12-month consensus analyst recommendation for Abbott Laboratories on January 18 is a “buy.”

    By Margaret Patrick
  • uploads///Chart  Healthcare
    Company & Industry Overviews

    GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth

    As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity.

    By Anirudha Bhagat
  • uploads///ABMD
    Company & Industry Overviews

    Do Analysts See Any Upside for Abiomed Stock?

    In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Exploring Abiomed’s Latest Performance Trends

    In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.

    By Kenneth Smith
  • uploads///MDT net income
    Company & Industry Overviews

    A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019

    Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.

    By Daniel Collins
  • uploads///analysis _
    Company & Industry Overviews

    How Wall Street Analysts View Medtronic in December

    Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”

    By Daniel Collins
  • uploads///hypertension _
    Company & Industry Overviews

    Taking Stock of Edwards Lifesciences’ Performance

    A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///XRAY
    Company & Industry Overviews

    What Does Dentsply’s Bottom-Line Trend Indicate?

    Dentsply Sirona’s interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter.

    By Kenneth Smith
  • uploads///HOLX
    Company & Industry Overviews

    What Analysts Recommend for Hologic Stock

    In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///SYK
    Company & Industry Overviews

    Analysts Remain Bullish on Stryker Stock

    In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///doctors office _
    Company & Industry Overviews

    How Stryker Is Positioned in November

    Stryker generated total revenues of $3.24 billion in the third quarter of 2018 as compared to $3.01 billion in the comparable period of 2017.

    By Kenneth Smith
  • uploads///checklist _
    Company & Industry Overviews

    Baxter International: Why Investors Are Interested

    Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///ALXN
    Company & Industry Overviews

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///ALXN
    Company & Industry Overviews

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.

    By Kenneth Smith
  • uploads///about _
    Earnings Report

    Merck & Co. Grows 5% in the Third Quarter

    Merck & Co. (MRK) released its Q3 2018 results today, reporting net revenues of $10.8 billion, or a 5% YoY (year-over-year) growth.

    By Daniel Collins
  • uploads///graph_
    Company & Industry Overviews

    Abbott Laboratories’ Nutrition Business: A Turnaround Story

    Abbott Laboratories (ABT) expects its nutrition business to have low- to mid-single-digit YoY revenue growth in fiscal 2018.

    By Margaret Patrick
  • uploads///lab _
    Earnings Report

    Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings

    Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.

    By Mike Benson
  • uploads///equipment _
    Company & Industry Overviews

    Abbott Laboratories: Why Analysts Are So Bullish

    The 12-month consensus recommendation for Abbott Laboratories on October 24 is a “buy” with a 12-month target price of $78.94.

    By Margaret Patrick
  • uploads///NVCR ana reco
    Earnings Report

    Gauging Analysts’ Views for NovoCure Stock

    Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”

    By Kenneth Smith
  • uploads///hospital _
    Earnings Report

    Zimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings

    Zimmer Biomet (ZBH) plans to release its Q3 earnings on October 26. Analysts expect ZBH to generate third-quarter revenues of $1.8 billion.

    By Daniel Collins
  • uploads///earnings estimates
    Earnings Report

    Edwards Lifesciences’ Q3 2018 Earnings Estimates

    Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.

    By Sarah Collins
  • uploads///sales estimates
    Earnings Report

    What to Expect of Edwards Lifesciences’ Q3 2018 Sales

    Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.

    By Sarah Collins
  • uploads///capsule _
    Company & Industry Overviews

    How Alexion Pharmaceuticals Is Positioned in October

    In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.

    By Kenneth Smith
  • uploads///freestyle libre
    Company & Industry Overviews

    ABT Expands in Europe with Freestyle Libre 2 Approval

    On October 1, ABT announced that it had received a CE mark in Europe for its next-generation continuous glucose monitoring system, the Freestyle Libre 2.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    ABT Stock Registered a 52-Week High in October

    On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

    By Mike Benson
  • uploads///COMPARISON
    Company & Industry Overviews

    EW Stock Returned More than the S&P 500’s Gain in 2018

    As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    High Valuation Multiples: Is EW Stock an Expensive Bet?

    On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    Is Abbott Laboratories Trading at a High Valuation in September?

    Abbott stock has been gaining momentum recently, and its valuation has improved.

    By Sarah Collins
  • uploads///COMPARISON
    Company & Industry Overviews

    ABT Returns Almost Double the S&P 500’s Year-to-Date Gain

    As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Stock Trades at Its 52-Week High in September

    On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.

    By Sarah Collins
  • uploads///hand _
    Company & Industry Overviews

    Do Abiomed’s Valuations Look Attractive?

    Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.

    By Mike Benson
  • uploads///analysis _
    Company & Industry Overviews

    How Analysts View Becton Dickinson in August 2018

    On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65.

    By Daniel Collins
  • uploads///blood _
    Earnings Report

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///mammography _
    Company & Industry Overviews

    Analysts’ Recommendations for Hologic and Its Peers in August

    Of the 19 analysts covering Hologic (HOLX) in August, five rated it as a “strong buy,” and seven rated it as a “buy.”

    By Margaret Patrick
  • uploads///health _
    Company & Industry Overviews

    Analyst Recommendations for Boston Scientific and Peers in June

    Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///computer _
    Company & Industry Overviews

    How Much Upside Do Analysts See in Baxter Stock?

    Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///woman _
    Company & Industry Overviews

    New Trial Data Show Improved Clinical Outcomes with HeartMate3

    On March 11, 2018, Abbott Laboratories (ABT) announced new late-breaking clinical trial data from its Momentum 3 study.

    By Sarah Collins
  • uploads///mitraclip
    Company & Industry Overviews

    MitraClip Drives Growth, Gets Reimbursement Approval in Japan

    On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.